Beta Bionics, Inc.
BBNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.79 | 0.08 | 0.00 |
| FCF Yield | -34.35% | -26.21% | -51.64% |
| EV / EBITDA | -2.89 | -2.97 | -1.49 |
| Quality | |||
| ROIC | -34.80% | -35.62% | -238.31% |
| Gross Margin | 55.11% | 52.59% | 100.00% |
| Cash Conversion Ratio | 0.88 | 0.74 | 0.93 |
| Growth | |||
| Revenue 3-Year CAGR | 613.89% | 2,289,010.46% | 563,474.08% |
| Free Cash Flow Growth | -57.30% | 46.13% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.53 | 0.65 | 0.37 |
| Interest Coverage | 0.00 | 0.00 | -4,703.14 |
| Efficiency | |||
| Inventory Turnover | 2.19 | 4.57 | 0.00 |
| Cash Conversion Cycle | 197.92 | 140.42 | 0.00 |